Drug-Drug Interactions Involving Dexamethasone in Clinical Practice : Myth or Reality?
Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug-drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump sharing localization and substrate affinities with CYP3A4, is a critical determinant of drug clearance, interindividual variability in drug disposition and clinical efficacy, and appears to be involved in the mechanism of numerous clinically relevant DDIs, including those involving dexamethasone. The recent increase in the use of high doses of dexamethasone during the COVID-19 pandemic have emphasized the need for better knowledge of the clinical significance of drug-drug interactions involving dexamethasone in the clinical setting. We therefore aimed to review the already published evidence for various DDIs involving dexamethasone in vitro in cell culture systems and in vivo in animal models and humans.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 22 vom: 15. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bourdin, Venceslas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytochrome P450 (CYP) 3A4 |
|---|
| Anmerkungen: |
Date Revised 27.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm12227120 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364939516 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364939516 | ||
| 003 | DE-627 | ||
| 005 | 20231226100622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12227120 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM364939516 | ||
| 035 | |a (NLM)38002732 | ||
| 035 | |a (PII)7120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bourdin, Venceslas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug-Drug Interactions Involving Dexamethasone in Clinical Practice |b Myth or Reality? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug-drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump sharing localization and substrate affinities with CYP3A4, is a critical determinant of drug clearance, interindividual variability in drug disposition and clinical efficacy, and appears to be involved in the mechanism of numerous clinically relevant DDIs, including those involving dexamethasone. The recent increase in the use of high doses of dexamethasone during the COVID-19 pandemic have emphasized the need for better knowledge of the clinical significance of drug-drug interactions involving dexamethasone in the clinical setting. We therefore aimed to review the already published evidence for various DDIs involving dexamethasone in vitro in cell culture systems and in vivo in animal models and humans | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a P-glycoprotein(P-gp) | |
| 650 | 4 | |a cytochrome P450 (CYP) 3A4 | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a drug–drug interaction | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a side effect | |
| 700 | 1 | |a Bigot, William |e verfasserin |4 aut | |
| 700 | 1 | |a Vanjak, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Burlacu, Ruxandra |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Champion, Karine |e verfasserin |4 aut | |
| 700 | 1 | |a Depond, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Amador-Borrero, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Sene, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Comarmond, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Mouly, Stéphane |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 22 vom: 15. Nov. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:22 |g day:15 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12227120 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 22 |b 15 |c 11 | ||